NCT04538794 - A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

January 17, 2023

Study Completion Date

January 17, 2023

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG

CDX-0159

Administered intravenously

DRUG

Normal Saline

Administered intravenously

Trial Locations (14)

Charite University, Berlin

National Allergy and Asthma Research, LLC, North Charleston

ForCare Clinical Research, Tampa

Sarasota Clinical Research, Sarasota

Clinical Research Center of Alabama, Birmingham

Bernstein Clinical Research Center, LLC, Cincinnati

Dawes Fretzin Clinical Research, Indianapolis

Midwest Allergy, Sinus and Asthma, SC, Normal

Kanarek Allergy Asthma & Immunology, Overland Park

AARA Research, Dallas

Treasure Valley Medical Research, Boise

Arizona Allergy & Immunology Research, Gilbert

Vital Prospects Clinical Research Institute, PC, Tulsa

Asthma, Nasal Disease & Allergy Research Center of New England, East Providence